Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0C5NT
|
|||
Drug Name |
PMID25666693-Compound-114
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Cancer related pain [ICD-11: MG30; ICD-10: R52.1, R52.2] | Patented | [1] | |
Inflammatory pain [ICD-11: MG30.42; ICD-10: R52, G89] | Patented | [1] | ||
Neuropathic pain [ICD-11: 8E43.0] | Patented | [1] | ||
Osteoarthritis pain [ICD-11: MG30.31] | Patented | [1] | ||
Company |
Shionogi & Co., Ltd. KUROSE, Noriyuki
|
|||
Structure |
Download2D MOL |
|||
Formula |
C20H21ClFN5O3S
|
|||
Canonical SMILES |
C1CN(CCN1C2=C(C=C(C=N2)CC(CO)O)Cl)C(=O)NC3=NC4=C(S3)C=C(C=C4)F
|
|||
InChI |
1S/C20H21ClFN5O3S/c21-15-8-12(7-14(29)11-28)10-23-18(15)26-3-5-27(6-4-26)20(30)25-19-24-16-2-1-13(22)9-17(16)31-19/h1-2,8-10,14,28-29H,3-7,11H2,(H,24,25,30)/t14-/m1/s1
|
|||
InChIKey |
GUCBTAMMWIOHHO-CQSZACIVSA-N
|
|||
PubChem Compound ID |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Transient receptor potential cation channel V1 (TRPV1) | Target Info | Antagonist | [1] |
Target's Patent Info | Transient receptor potential cation channel V1 (TRPV1) | Target's Patent Info | [1] | |
KEGG Pathway | Neuroactive ligand-receptor interaction | |||
Inflammatory mediator regulation of TRP channels | ||||
NetPath Pathway | IL2 Signaling Pathway | |||
Pathway Interaction Database | Trk receptor signaling mediated by the MAPK pathway | |||
Trk receptor signaling mediated by PI3K and PLC-gamma | ||||
Reactome | TRP channels |
References | Top | |||
---|---|---|---|---|
REF 1 | Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.